|
|
2755 Bristol Street, Suite 285
Cosa Mesa, CA 92626-5985 USA
phone:
714-545-3288
fax:
866-294-2611 |
| Symbol |
CNSO |
| Exchange |
OTCBB |
| Founded |
2000 |
| Employees |
20 |
|
|
www.cnsresponse.com |
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| rEEG technology for the assessment of neurophysiological abnormalities and determination of psychiatric treatment |
 |
| Management |
| Leonard Brandt, Chief Executive Officer; George Carpenter, President; Daniel A. Hoffman, M.D., Chief Medical Officer; Mark Desrosiers, Senior Vice President Commercial Operations; Brian MacDonald, Chief Engineer; Ken Graap, Director of Network Services; Barry Kass, Clinical Liaison, National Business Development; Michael Metzig, Manager of Laboratory Services; Mark Schiller, MD; Meyer Proler, M.D., President, University Neurodiagnostics |
|
|
|
|
| Keywords |
| depression, diagnostics, neurology, psychiatry, mental, reeg, behavioral disorders, anorexia, bulimia, drug addiction, addictions |
|
|
|
|
Description |
| CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports that specifically assist physicians in developing personalized treatment strategies based on the patient's unique physiology. |
 |
| Products / Services |
Referenced-EEG (rEEG) is a patented broad-based system of CNS physiologic markers used to guide treatment of behavioral and addictive illness. It enhances a physician's ability to manage psychiatric medications in patients from 6 to 90 years of age and has been proven useful for a broad range of research and clinical applications, including mood, anxiety, eating, obsessive-compulsive, traumatic, personality, and addictive disorders. rEEG has been particularly beneficial in so-called treatment-refractory patients, or patients who have undergone numerous medication treatment trials with unsatisfactory results.
|
 |
| Technology / Differentiation |
| Medical treatment of mental disorders differs fundamentally from the treatment of all other health disturbances in that psychiatrists or addiction specialists have no objective physiologic brain measurement systems available to guide treatment of mental or addictive illness. rEEG uses digital electroencephalography in conjunction with a normative database and a proprietary clinical database to identify abnormal patient physiology. Appropriate medications are then statistically selected specifically to normalize discovered abnormalities. This process has been correlated to treatment outcome in a database of over 1,600 patients and 13,000 medication trials. The results of the analysis for each patient are produced in a two-page report provided to the physician from the CNS reference laboratory. |
 |
| Market / Customers |
The psychiatric treatment market accounts for 7.4% of healthcare spending, second only to heart disease. In the U.S., depression affects more than 18.8 million people; physicians write 11 million prescriptions for depression per month. Other central nervous system disorders targeted by the company include anxiety, addiction, eating disorders and schizophrenia.
|
 |
| Status |
| The results from a study conducted by the Center for Health Economics, Epidemiology, and Science Policy at United BioSource Corporation (a global pharmacoeconomic research firm) released in November 2008 have indicated that the use of CNS Response's rEEG-Guidance for treatment resistant depression is "superior to the American Psychiatric Association treatment guidelines." Another study from the Analysis Group (a national consulting firm), published in October 2008, demonstrated that the company's technology can significantly decrease the costs of mental health treatment. |
 |
|
|
|
|